Embecta Corp logo

Embecta Corp(EMBC)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$6.46
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for EMBC

11/13/2026: EMBC (1-star) is currently NOT-A-BUY. Pass it for now.

Embecta Corp. is a medical device company specializing in diabetes management tools, prominently featuring insulin pen needles and safety injection devices. The company benefits from a well-established global distribution footprint, consistent operating margins, and a disciplined focus on balance sheet deleveraging. However, its primary growth challenge stems from secular pressure as patients transition toward automated insulin pumps and continuous monitoring systems. To counter this, Embecta is actively pursuing strategic diversification into GLP-1 drug delivery platforms and smart auto-injectors. The stock appeals primarily to value-oriented investors willing to monitor execution risks as the business navigates technological shifts in chronic care.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitEmbecta's core legacy revenue is currently contracting rather than expanding rapidly.
Momentum investorStrong fit while signal remains positiveMomentum fit depends heavily on a positive technical breakout or short-term reversal signal.
Value investorMixed fitThe stock trades at a very low trailing P/E multiple, though structural headwinds present ongoing risks.
Dividend investorMixed fitThe company offers a notable dividend yield, but dividend safety is tied to managing declining legacy cash flows.
Low-risk investorWeak fitSignificant price volatility and secular technology threats create elevated risks for conservative capital.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock has experienced sharp fluctuations driven by market sentiment and shifting sector valuations.
Valuation riskMediumLow headline valuation multiples reflect deep skepticism regarding long-term revenue growth.
Competition risk (insulin pumps and tech substitution)HighRapid adoption of automated insulin delivery systems poses an ongoing threat to traditional pen needle demand.
Business qualityMediumEmbecta possesses robust manufacturing scale and solid margins, but lacks high-growth software or tech moats.
Dividend incomeMedium / highWhile income payouts exist, maintaining them depends on stable cash conversion amid top-line pressures.
Execution riskMedium / highSuccessfully pivoting into GLP-1 delivery platforms and integrating recent acquisitions is crucial for future stability.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 366.02M USD
Price to earnings Ratio 4.39
1Y Target Price 4
Price to earnings Ratio 4.39
1Y Target Price 4
Volume (30-day avg) 844.7K shares
Beta 0.81
52 Weeks Range 2.76 - 14.33
Updated Date 11/15/2026
52 Weeks Range 2.76 - 14.33
Updated Date 11/15/2026
Dividends yield (FY) 7.15%
Basic EPS (TTM) 1.47

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Instruments & Supplies

BUY participation
60.0%
Active BUY / eligible
3 / 5
30-Day BUY Count Change
+1

Eligible universe: 5 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 68.15%
Avg. Invested days 37
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
EMBC receives a 4-star rating, supported by strong unit economics, and solid company fundamentals. The rating is constrained by soft analyst coverage, weak price momentum, and limited analyst upside.

Company Fundamentals

★★★★★
EMBC has solid overall fundamentals (4 stars), with solid financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, solid earnings growth (+21.8%) and strong cash generation (FCF margin 16.9%) are partially offset by slightly negative revenue growth (-3.8%), soft profitability (net margin 8.8%), modest insider ownership of 3.45%.

Financial Health Rating

★★★★★
EMBC's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 33.9%). Overall financial-health metrics support a 4-star score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is EMBC's strongest growth driver at +816.6% FY2025 versus FY2024 (strong, 5 stars). By comparison, earnings growth (+21.8%, solid) is also solid, while revenue growth (-3.8%, slightly negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 93.2% and approximately 96.7% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 3.45% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 8.12%
Yacktman Asset Management Co 7.62%
Vanguard Capital Management, LLC 4.51%
Deerfield Management Co 4.47%
Jefferies Financial Group Inc 4.16%

Unit Economics (Per $1K Revenue)

★★★★★
EMBC generates approximately $629 of gross profit, $305 of operating income, and $169 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong margins, cash conversion, and capital efficiency support the rating.

Economic Dimensions

★★★★★
Effective Tax Rate: 30.01%

Quantitative Style Profile

★★★★★
EMBC has a high-quality, liquid profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedQuality TiltSmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Pen Needles and SyringesGlobal sales of insulin pen needles, conventional syringes, and safety injection devices sold to wholesalers and distributors.This is the primary legacy cash cow that generates the vast majority of the company's revenues.
Geographic Exposure (U.S. vs International)Operations divided roughly evenly between the United States and international markets spanning over 100 countries.Geographic diversification helps insulate the company somewhat from localized reimbursement or pricing pressures.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE 4.39
Forward PE -
Enterprise Value 1.64B
Price to Sales(TTM) 0.36
Enterprise Value 1.64B
Price to Sales(TTM) 0.36
Enterprise Value to Revenue 1.61
Enterprise Value to EBITDA 6.16
Shares Outstanding 56.66M
Shares Floating 54.80M
Shares Outstanding 56.66M
Shares Floating 54.80M
Percent Insiders 3.45
Percent Institutions 93.17

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.